Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Seaforth ...

oh and srandl

in response to by
posted on May 23, 2008 11:25AM

Now we have a CEO who agrees with what I was saying 2 years ago :)



While no specific timeline has been outlined as we move toward an operating company with products, customers, and markets, the company expects not to make further dividend distributions, choosing to instead, use the cash and capital assets (stock) of the company to pursue its M&A efforts. It is unusual for emerging technology companies to pay dividends as they generally retain earnings to grow their businesses by funding future product R&D and expanding marketing and sales efforts. It is our plan to move the company in that direction.





Share
New Message
Please login to post a reply